Johnson & Johnson $JNJ Stake Lowered by Broderick Brian C

Key Points

• Broderick Brian C reduced its stake in Johnson & Johnson by 6.3% in the 2nd quarter, now holding 72,114 shares valued at approximately $11 million.
• Several institutional investors, including Vanguard Group Inc. and Bank of New York Mellon Corp, increased their holdings in Johnson & Johnson during the 1st quarter of this year.
• Johnson & Johnson reported earnings per share of $2.77 for the last quarter, exceeding estimates, with revenue increasing by 5.8% year-over-year, and a quarterly dividend of $1.30 was declared.

Broderick Brian C cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,114 shares of the company's stock after selling 4,833 shares during the quarter. Johnson & Johnson makes up 2.2% of Broderick Brian C's portfolio, making the stock its 20th largest holding. Broderick Brian C's holdings in Johnson & Johnson were worth $11,015,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after buying an additional 1,170,120 shares in the last quarter. Northern Trust Corp grew its holdings in Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after buying an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock worth $3,133,602,000 after buying an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after buying an additional 448,666 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $190.97 on Friday. The company's fifty day moving average is $178.01 and its two-hundred day moving average is $163.56. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10. The company has a market cap of $459.92 billion, a P/E ratio of 20.42, a price-to-earnings-growth ratio of 2.42 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the business earned $2.82 EPS. The company's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Citigroup upped their target price on Johnson & Johnson from $200.00 to $213.00 and gave the stock a "buy" rating in a research report on Tuesday. Bank of America upped their target price on Johnson & Johnson from $175.00 to $198.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an "overweight" rating in a research report on Friday, October 3rd. Finally, UBS Group set a $198.00 price objective on Johnson & Johnson in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $191.41.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.